Bristol-Myers Squibb And Medarex To Refile Oncology Agreement With FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission requests additional information related to Bristol's $192 mil. development agreement for Medarex' metastatic melanoma agent. The extended review period is expected to expire in January.
You may also be interested in...
Bristol To Devote $125 Mil. To Develop Medarex' Metastatic Melanoma Agent
Bristol adds Phase III anti-CTLA-4 product MDX-010 to its franchise as several of its oncologics are exposed to generic competition. Medarex cites upside potential as a reason for entering into the collaboration with Bristol.
Lupus Guidance Suggests Broad Use Of Health-Related Quality Of Life Endpoint
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.
RiskMAP Guidance Includes Plans For A Website
FDA is planning to develop a Risk Minimization Action Plan website, an agency risk management guidance states